Fixed-dose subcutaneous (SC) trastuzumab and pertuzumab (HP) (Phesgo®) offers a clinically non-inferior alternative to intravenous (IV) administration for HER2-positive breast cancer, with potential advantages in treatment efficiency. The gene discussed is ERBB2; the disease is breast carcinoma.